The State Council Joint Prevention and Control Mechanism held a press conference on January 9th to introduce the recent epidemic prevention and control and vaccination. Let’s watch together!
China has carried out more than 9 million doses of COVID-19 vaccination.
Since December 15th, China officially launched the vaccination work of COVID-19, a key population in China, the vaccination amount of the national key population has reached nearly 7.5 million doses. Together with the previous 1.6 million doses for high-risk population, China has carried out more than 9 million doses of Covid-19 vaccination, which further proves the good safety of Covid-19 vaccine in China.
Vaccination in Covid-19 is free for all, which is shared by the medical insurance fund and finance.
COVID-19 vaccination, a key population, started on December 15th, is organized and arranged by governments at all levels, and individuals do not bear the cost of vaccination and vaccination. In the case of collecting personal expenses in some places, we issued a document in the name of the Comprehensive Group of the State Council Joint Prevention and Control Mechanism, requesting immediate rectification.
After the conditional listing of vaccines, the free vaccination of vaccines is carried out on the premise that residents are informed and willing. The expenses of vaccines provided by enterprises at the agreed price, plus all the expenses of vaccination services, will be borne by the medical insurance fund and the finance, and the individual residents will not bear it, nor will it affect the treatment of everyone.
There is no contradiction between the pricing of vaccines in COVID-19 and free vaccination for all.
Enterprises will have costs in the process of developing vaccine research and development, production, storage and transportation, so enterprises will make corresponding pricing according to the attributes of COVID-19 vaccine public products and the costs. Relevant government departments will also purchase from enterprises in accordance with corresponding procedures and at corresponding prices, and provide free vaccination for the whole people.
COVID-19 vaccine can be traced back to the whole process.
We have set up a total of 25,392 vaccination sites in China, established the registration of vaccines in and out of the warehouse, and established a set of traceability management system from the storage, transportation and use of vaccines. At the same time, focus on strengthening the monitoring of suspected abnormal reactions through information management. According to the vaccine demand plan of each province, various methods such as precise deployment, speeding up turnover and docking demand are adopted to ensure vaccine supply.
People with allergies, fever and pregnant women cannot be vaccinated with COVID-19 vaccine.
If the recipient is allergic to the vaccine or the ingredients of the vaccine, he cannot be vaccinated.
The recipient is in the acute stage of illness or in the acute stage of chronic diseases, as well as fever or pregnancy, and can not be vaccinated for the time being.
With the understanding of diseases and the deepening of vaccine research, the taboo of vaccination will also be adjusted and improved.
The serious adverse reaction of vaccine is about one in a million.
According to the monitoring results, 80% of the suspected adverse reactions reported by vaccines in China are general adverse reactions, of which 6 out of 100,000 are abnormal reactions, and most of the abnormal reactions are allergic skin rash. Of course, there are other allergic reactions, including angioedema and other adverse reactions, and the serious adverse reactions are about one in a million. Compared with historical data, there is no abnormality. In addition, when reminding the recipients to vaccinate, they should truthfully inform the vaccinator of their health status, and after vaccination, they should stay on the spot for 30 minutes.
The current virus mutation will not affect the vaccine protection.
From the beginning, we set up a special research group to study and monitor the variation in Covid-19. In addition, two scientific research institutes have done special research recently, one is the Institute of Medical Laboratory Animals of China Academy of Medical Sciences, and the other is the Institute of Virology of Sun Yat-sen University. They compared the viruses that appeared in China in January, February, March, April, May and June with the mutant strains in Britain this time, and found that the antibodies produced by COVID-19 vaccine immunized monkeys and immunized humans can neutralize the early virus strains in China and the mutant virus strains in Britain. This result also strengthened our confidence that our vaccine has the same neutralization ability for such a mutant. At least for now, it is very clear that the mutation of this virus will not affect the protection of the vaccine.
At present, it seems that the mutation rate in Covid-19 is still within the acceptable range, and the mutation rate is not particularly fast. We should continue to closely monitor the virus variation, make preparations in advance, and carry out research on broad-spectrum COVID-19 vaccine or mutated COVID-19 vaccine, so as to effectively deal with possible problems.
Hebei should complete vaccination for key populations as soon as possible.
According to the national vaccination plan for key populations, Hebei Province has vaccinated nearly 140,000 people, so it is necessary to speed up the progress and complete the vaccination for key populations as soon as possible. Whether to adjust the vaccination strategy according to the epidemic situation in Shijiazhuang, the provincial capital of Hebei Province should make overall consideration according to the needs of the whole prevention and control work, including the characteristics of vaccines and other comprehensive factors.